WEBINAR

Rapid Intact Charge Variant Analysis with Coupled icIEF-MS

Watch, On Demand! 
WebinarsBY-TN-White

 

 

 

 

Testing is required to monitor modifications in biopharmaceutical development, from clone selection to manufacturing. However, current testing approaches for intact proteins are time-consuming and don’t provide real-time analytics to drive decision making.
 Read More Below

Brought to you by

PM-intrabio

WATCH THE WEBINAR NOW

Webinar Summary

Testing is required to monitor modifications in biopharmaceutical development, from clone selection to manufacturing. However, current testing approaches for intact proteins are time-consuming and don’t provide real-time analytics to drive decision making.

In this webinar, Eric Carlson, President and CEO of Protein Metrics, will demonstrate how the Byos® Vendor-neutral Mass Spec Analysis platform, enables efficient analysis of Intact data for Critical Quality Attributes (CQAs).

Erik Gentalen will share how Intabio’s Blaze platform utilizes microfluidic icIEF technology coupled with mass spectrometry to characterize intact protein charge variant with 100-fold higher throughput at a fraction of the cost of traditional approaches.

John Teare, VP, Biological Development & Manufacturing at Coagulent Therapeutics, will discuss how his company is using these technologies for some of the most challenging research: coagulation factors for bleeding disorders.

From this webinar, you will learn how to:

• Achieve high throughput analysis of biologics
• Efficiently analyse charge variants in biologics development
• Achieve high throughput CQAs (Critical Quality Attributes) monitoring
• Work with multiple mass spec vendors
• Speed up the development of biopharmaceuticals and therapeutic proteins

Speaker Information:


WebinarSpeakerImage-(002)
Eric Carlson, Ph.D.
President and CEO
Protein Metrics Inc.

Erik-Gentalen-Headshot-Complete
Erik Gentalen
CTO and VP of Intellectual Property
Intabio, Inc.

John-Teare-Headshot---complete
John Teare, Ph.D.
VP CMC
Coagulant Therapeutics Corporation